Methods of Treating Flushing Associated with Carcinoid Tumors and Carcinoid Syndrome
A method of treating flushing associated with carcinoid tumors and carcinoid syndrome in a patient in need thereof comprising topically applying a pharmaceutical composition comprising an effective amount of an alpha adrenergic receptor agonist, pharmaceutically acceptable salt thereof, or combinations thereof; and a pharmaceutically acceptable carrier to the site of the flushing is claimed.
1 . A method of treating flushing associated with carcinoid tumors and carcinoid syndrome in a patient in need thereof comprising topically applying a pharmaceutical composition comprising an effective amount of an alpha adrenergic receptor agonist, pharmaceutically acceptable salt thereof, or combinations thereof; and a pharmaceutically acceptable carrier to the site of the flushing.
2 . A method according to claim 1 , where the site of the flushing is the face or the neck.
3 . A method according to claim 1 , wherein the alpha adrenergic receptor agonist is an alpha-1 adrenergic receptor agonist or an alpha-2 adrenergic receptor agonist.
4 . A method according to claim 1 , wherein the alpha-1 adrenergic receptor agonist or alpha-2 adrenergic receptor agonist is brimonidine, tetrahydrozaline, naphazoline, xylometazoline, epinephrine, norepinephrine, oxymetazoline, phenylephrine, or methoxyamine.
5 . A method according to claim 1 , wherein the alpha-2 adrenergic receptor agonist is brimonidine or pharmaceutically acceptable salts thereof.
6 . A method according to claim 1 , wherein the pharmaceutically acceptable carrier is a gel, cream, ointment, lotion, or emulsion.
7 . A method according to claim 1 , wherein the brimonidine or pharmaceutically acceptable salt thereof is present in an amount of from about 0.5% by weight to about 5% by weight of the composition.
8 . A method according to claim 1 , wherein the brimonidine or pharmaceutically acceptable salt thereof is present in an amount of from about 0.5% by weight to about 2% by weight of the composition.
9 . A method according to claim 1 , wherein the carrier is a gel and the brimonidine or pharmaceutically acceptable salt thereof is present in an amount of about 0.33% by weight of the gel.